PE20130751A1 - Inhibidores de oxadiazol de la produccion de leucotrieno - Google Patents

Inhibidores de oxadiazol de la produccion de leucotrieno

Info

Publication number
PE20130751A1
PE20130751A1 PE2013000279A PE2013000279A PE20130751A1 PE 20130751 A1 PE20130751 A1 PE 20130751A1 PE 2013000279 A PE2013000279 A PE 2013000279A PE 2013000279 A PE2013000279 A PE 2013000279A PE 20130751 A1 PE20130751 A1 PE 20130751A1
Authority
PE
Peru
Prior art keywords
phenyl
oxadiazol
alkyl
compounds
butan
Prior art date
Application number
PE2013000279A
Other languages
English (en)
Inventor
Alessandra Bartolozzi
Alan Olague
Todd Bosanac
Zhidong Chen
Lombaert Stephane De
John D Huber
Ho-Yin Lo
Piu Leng Loke
Weimin Liu
Tina Marie Morwick
Doris Riether
Heather Tye
Lifen Wu
Renee M Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130751(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20130751A1 publication Critical patent/PE20130751A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXADIAZOL DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H, ALQUILO(C1-C7) O CARBOCICLO(C3-C10); R3 ES HETEROARILO DE 5 A 11 MIEMBROS OPCIONALMENTE SUSTITUIDO CON ALCOXI(C1-C5), HALOGENO, -O-BENCILO, ENTRE OTROS; R4 ES H, ALQUILO(C1-C3), HALOGENO O NITRILO; R5 ES ALQUILO(C1-C6), CARBOCICLO(C3-C10), HETEROCICLO DE 3 A 11 MIEMBROS, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(3-{2-[4-(5-METOXIPIRIDIN-3-IL)FENIL]-3-METILBUTAN-2-IL}-1,2,4-OXADIAZOL-5-IL)PIRAZINA; 5-{4-[3-METIL-2-(5-FENIL-1,2,4-OXADIAZOL-3-IL)BUTAN-2-IL]FENIL}PIRIMIDIN-2-AMINA; 5-(4-{3-METIL-2-[5-(PIRIDIN-3-IL)-1,2,4-OXADIAZOL-3-IL]BUTAN-2-IL}FENIL)PIRIMIDIN-2-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA ACTIVADORA DE LA 5-LIPOXIGENASA (FLAP) SIENDO UTILES EN EL TRATAMIENTO DE ASMA, ALERGIA, ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, ATEROSCLEROSIS
PE2013000279A 2010-08-16 2011-08-11 Inhibidores de oxadiazol de la produccion de leucotrieno PE20130751A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37392510P 2010-08-16 2010-08-16
US201161492176P 2011-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
PE20130751A1 true PE20130751A1 (es) 2013-06-21

Family

ID=44511591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000279A PE20130751A1 (es) 2010-08-16 2011-08-11 Inhibidores de oxadiazol de la produccion de leucotrieno

Country Status (22)

Country Link
US (1) US8658661B2 (es)
EP (1) EP2606045B1 (es)
JP (1) JP5619284B2 (es)
KR (1) KR20130100105A (es)
CN (1) CN103180314A (es)
AP (1) AP2013006678A0 (es)
AR (1) AR082696A1 (es)
AU (1) AU2011292285A1 (es)
BR (1) BR112013003439A2 (es)
CA (1) CA2807364A1 (es)
CL (1) CL2013000455A1 (es)
CO (1) CO6680645A2 (es)
EA (1) EA201300250A1 (es)
EC (1) ECSP13012494A (es)
MX (1) MX2013001872A (es)
NZ (1) NZ605690A (es)
PE (1) PE20130751A1 (es)
SG (1) SG187549A1 (es)
TW (1) TW201238947A (es)
UY (1) UY33557A (es)
WO (1) WO2012024150A1 (es)
ZA (1) ZA201300238B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187549A1 (en) 2010-08-16 2013-03-28 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012040139A1 (en) * 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
US9199904B2 (en) * 2011-03-18 2015-12-01 Boehringer Ingelheim International Gmbh Process for preparing carboxylic acids
US9174980B2 (en) * 2012-01-31 2015-11-03 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
WO2013119751A1 (en) * 2012-02-09 2013-08-15 Boehringer Ingelheim International Gmbh Process for preparing carboxamidine compounds
EP2746279A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
WO2014095381A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746256A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746277A1 (en) 2012-12-19 2014-06-25 Basf Se Fungicidal imidazolyl and triazolyl compounds
CN103724279B (zh) * 2014-01-20 2016-04-06 新发药业有限公司 一步成环制备2-甲基-4-氨基-5-氨基甲基嘧啶的便捷合成方法
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141019A (en) * 1964-07-14 Chaohj
GB1053825A (es) * 1963-03-22
JP2719742B2 (ja) * 1991-04-30 1998-02-25 株式会社大塚製薬工場 フェニルチアゾール誘導体
KR20010014049A (ko) * 1997-07-10 2001-02-26 디르크 반테 Ｉｌ-5를 저해하는 6-아자우라실 유도체
EP0987265A1 (en) * 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
DE60026312T2 (de) 1999-08-06 2006-12-21 Janssen Pharmaceutica N.V. Interleukin-5 hemmende 6-azauracil derivate
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
CA2584262A1 (en) * 2004-10-18 2006-04-27 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhiibitors
NZ565494A (en) * 2005-08-10 2011-06-30 Glaxosmithkline Llc Xanthine derivatives as selective HM74A agonists
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
US20070219206A1 (en) * 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
AU2007238878A1 (en) * 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
US20070287699A1 (en) * 2006-05-01 2007-12-13 Virobay, Inc. Antiviral agents
ES2376396T3 (es) * 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
ATE543810T1 (de) * 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
FR2906866A1 (fr) * 2006-10-10 2008-04-11 Felix Ifrah Luminaire comprenant au moins un moyen d'eclairage dont l'activation s'effectue par l'emission d'un rayonnement lumineux
WO2008050200A1 (en) * 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
EP2148878A4 (en) 2007-04-20 2011-08-10 Merck Canada Inc NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
CA2702225A1 (en) 2007-10-10 2009-04-16 Merck Sharp & Dohme Corp. Diphenyl substituted cycloalkanes
CA2749893A1 (en) * 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
MX2012013031A (es) 2010-05-12 2012-12-17 Univ Vanderbilt Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica.
SG187549A1 (en) 2010-08-16 2013-03-28 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤

Also Published As

Publication number Publication date
EP2606045B1 (en) 2016-01-06
WO2012024150A1 (en) 2012-02-23
CN103180314A (zh) 2013-06-26
ZA201300238B (en) 2014-06-25
CL2013000455A1 (es) 2013-05-03
US8658661B2 (en) 2014-02-25
AU2011292285A1 (en) 2013-01-31
JP5619284B2 (ja) 2014-11-05
JP2013534245A (ja) 2013-09-02
KR20130100105A (ko) 2013-09-09
EP2606045A1 (en) 2013-06-26
UY33557A (es) 2012-03-30
TW201238947A (en) 2012-10-01
CO6680645A2 (es) 2013-05-31
US20120220561A1 (en) 2012-08-30
BR112013003439A2 (pt) 2019-09-24
MX2013001872A (es) 2013-09-02
NZ605690A (en) 2014-06-27
EA201300250A1 (ru) 2013-08-30
AR082696A1 (es) 2012-12-26
CA2807364A1 (en) 2012-02-23
ECSP13012494A (es) 2013-04-30
SG187549A1 (en) 2013-03-28
AP2013006678A0 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
PE20130751A1 (es) Inhibidores de oxadiazol de la produccion de leucotrieno
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20140865A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20090775A1 (es) Nuevos derivados de biarilo
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20081532A1 (es) Compuestos novedosos
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
PE20081889A1 (es) Indol carboxamidas como inhibidores de ikk2
PE20141375A1 (es) Activadores de glucoquinasa
CO6260017A2 (es) Compuestos de oxazol, oxadiazol y tiadiazol utiles para el control de nematodos
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20120632A1 (es) Inhibidores de bace
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20090150A1 (es) Compuestos derivados de oxadiazol
PE20110906A1 (es) Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
PE20090815A1 (es) Compuesto de amida
PE20131398A1 (es) Inhibidores de oxadiazol de la produccion de leucotrienos
PE20081353A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
PE20081199A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed